ACE inhibitor use in elderly patients with systolic left ventricular dysfunction: problems and opportunities

Related Experiment Video

Updated: Sep 12, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

B Pitt1

  • 1University of Michigan School of Medicine, USA.

British Journal of Clinical Practice. Supplement
|July 1, 1996
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitors help heart failure patients, but side effects limit use, especially in the elderly. Angiotensin II receptor blockers offer a promising alternative for this population.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • ACE inhibitors reduce morbidity and mortality in post-infarction and systolic left ventricular dysfunction patients.
  • Bradykinin-induced side effects limit ACE inhibitor tolerance, particularly in elderly individuals.

Purpose of the Study:

  • To evaluate the potential of angiotensin II type I receptor antagonists as an alternative treatment for elderly patients.
  • To explore the role of angiotensin II type I receptor antagonists in systolic left ventricular dysfunction compared to ACE inhibitors.

Main Methods:

  • Clinical trials comparing ACE inhibitors and angiotensin II type I receptor antagonists.
  • Investigation into optimal dosing and combination therapies involving ACE inhibitors, aspirin, and NSAIDs.

Main Results:

  • Angiotensin II type I receptor antagonists block angiotensin II effects without increasing bradykinin, potentially improving elderly patient tolerance.
  • Ongoing research directly compares these antagonists with ACE inhibitors in systolic left ventricular dysfunction.

Conclusions:

  • While ACE inhibitors are established in heart failure, their application, especially in the elderly, is still evolving.
  • Angiotensin II type I receptor antagonists represent a significant area of investigation for improving heart failure management in vulnerable populations.

More Related Videos

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery08:17

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...